tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
SGEN is currently covered by 18 analysts with an average price target of $241.52. This is a potential upside of $12.64 (5.52%) from yesterday's end of day stock price of $228.88.
Seagen's activity chart (see below) currently has 321 price targets and 216 ratings on display. The stock rating distribution of SGEN is 65.79% BUY and 34.21% HOLD.
Analysts average stock forecasts to be materialized ratio is 87.75% with an average time for these price targets to be met of 129.48 days.
Highest price target for SGEN is $216, Lowest price target is $131, average price target is $241.52.
Most recent stock forecast was given by ASTHIKA GOONEWARDENE from TRUIST on 18-Oct-2023. First documented stock forecast 31-Oct-2014.
Seagen is a biotechnology company that specializes in the development and commercialization of innovative cancer treatments. The company’s primary revenue channel is from the sales of its oncology products, including ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TUKYSA® (tucatinib), among others.
ADCETRIS is an antibody-drug conjugate that targets CD30-expressing lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
PADCEV is an antibody-drug conjugate that targets Nectin-4-expressing solid tumors, including bladder and urothelial cancers.
TUKYSA is a small molecule kinase inhibitor that targets HER2-expressing cancers, including breast cancer.
Seagen also generates revenue through collaborations and partnerships with other pharmaceutical and biotech companies.
For example, the company has partnerships with Genmab A/S, Bristol Myers Squibb, and Astellas Pharma, among others, for the development and commercialization of new cancer therapies.
Seagen Inc. also generates revenue through its manufacturing capabilities. The company has manufacturing facilities in Bothell, Washington, and Switzerland, which are used to produce its own products, as well as products for its partners.
Seagen’s headquarters is in Bothell, Washington. It was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020.
Currently out of the existing stock ratings of SGEN, 25 are a BUY (65.79%), 13 are a HOLD (34.21%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$229
$0.26 (0.11%)
$229
1 years 1 months 5 days ago
(18-Oct-2023)
1/4 (25%)
$14.15 (6.59%)
45
Hold
$229
$0.26 (0.11%)
$173
1 years 3 months 20 days ago
(03-Aug-2023)
17/19 (89.47%)
$35.5 (18.35%)
135
Hold
$170
$-58.74 (-25.68%)
$170
1 years 7 months 30 days ago
(24-Mar-2023)
2/3 (66.67%)
$-27.64 (-13.99%)
121
Hold
$229
$0.26 (0.11%)
$170
1 years 7 months 30 days ago
(24-Mar-2023)
1/2 (50%)
$31.36 (15.87%)
33
Hold
$229
$0.26 (0.11%)
$163
1 years 8 months 2 days ago
(21-Mar-2023)
6/7 (85.71%)
$29.09 (14.55%)
125
What is SGEN (Seagen) average time for price targets to be met?
Which analyst has the current highest performing score on SGEN (Seagen) with a proven track record?
Which analyst has the most public recommendations on SGEN (Seagen)?
Which analyst is the currently most bullish on SGEN (Seagen)?
Which analyst is the currently most reserved on SGEN (Seagen)?
